Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939664 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL214038 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL7531612 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL789155 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL22389997 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL24340313 | 0.96 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL15817493 | 0.92 | — | — | |
| SCHEMBL3814583 | 0.92 | — | — | |
| SCHEMBL8237916 | 0.90 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 | |
| SCHEMBL6156333 | 0.90 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1PKMMAPK1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112403513-A | Chiral catalyst of triethylene diamine derivative and synthesis method thereof | 桂林理工大学 | 2021-02-26 | — | — | CN | claimed |
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-116419753-A | Heterocyclic compounds as BCL-2 inhibitors | 北京诺诚健华医药科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| EP-4194454-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3820574-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | Novartis AG (CH) | 2021-05-19 | — | — | EP | disclosed |
| CN-112403513-A | Chiral catalyst of triethylene diamine derivative and synthesis method thereof | 桂林理工大学 | 2021-02-26 | — | — | CN | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| EP-2616460-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | Otsuka Pharmaceutical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| WO-2008005368-A2 | PIPERAZINES AS P2X7 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BCL2, BCL2L11, BCL2L2 | L3MBTL1 2222/4885ALDH1A1 2127/4885PKM 2737/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | L3MBTL1 303/4885ALDH1A1 1739/4885PKM 1398/4885 |
| US-20200281951-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | L3MBTL1 516/4885ALDH1A1 2027/4885PKM 2807/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | L3MBTL1 516/4885ALDH1A1 2027/4885PKM 2807/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | L3MBTL1 4681/4885ALDH1A1 852/4885PKM 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.